General Vaccines

Streamlined Vaccine Development and Bioproduction

Look to MaxCyte’s fully scalable, cGMP-compliant delivery platform to develop innovative vaccines and optimized manufacturing that offer shorter lead times and greater production flexibility while maintaining vaccine safety. No other delivery platform offers the ability to develop and manufacture the full complement of next-generation vaccines

  • Rapid, high titer protein production including multi-subunit proteins
  • >90% cell viability and transfection efficiency of a broad range of cell types including insect cells
  • Capable of efficiently delivering multiple and/or large plasmids
  • Computer-controlled, closed environment for consistent results
  • Clear regulatory pathway – cGMP compliant and FDA Master File

APPLICATIONS INCLUDE:

Recombinant Protein & Antigen Production

Antibodies

VLP/VRP Production

Dendritic Cell Vaccines

 

Explore the Maxcyte Difference

 

High Cell Viability Enables Increased Productivity

CHO cells were transfected with a gp145 expression plasmid via small-scale electroporation (8×107), large-scale electroporation (2×109) or a customer’s optimized PEI process.  Transfected cells were inoculated into shake flasks at the same cell density and cultured for 10 days.

VLP Production in Days Without the Need for Baculoviruses

Sf9 cells were transfected with a plasmid encoding three VLP antigens. In tandem, a baculovirus (BV) expression system was used to produce VLPs containing the identical three antigens. SDS-PAGE analysis of cell supernatants (48 hrs post transfection/infection) shows the presence of the three VLP antigens in all electroporation and BV samples; however, BV protein contaminants were also present in supernatants from BV-infected cells, creating purification challenges, and yield loss.

Significantly Higher VRP Production

 

Vero cells were transfected with mRNA and/or plasmid DNA encoding alphavirus replicon components using the MaxCyte STX. Transfected cells were plated in standard tissue culture vessels, and secreted viral replicon particles were quantified using conventional titer assays. Similar studies using the same cells and mRNA or plasmid DNA were conducted using alphavirus ‘best practice’ methods. When both RNA replicons and RNA helpers were used, electroporation lead to 9x higher relative titers of both the GFP and HIV gag-expressing VRPs over the current best practice method.

 

Resource Center

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Request Demo